Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Howard A. Burris(Deaconess Hospital), Daniel D. Von Hoff(Translational Genomics Research Institute), M. Christine Cripps(The University of Texas at San Antonio Health Science Center), F. Andrew Dorr(The University of Texas at San Antonio Health Science Center), M R Green(The University of Texas at San Antonio Health Science Center), Anna Maria Storniolo(Indiana University Health), Russell K. Portenoy(Albert Einstein College of Medicine), Ryan Nelson(The University of Texas at San Antonio Health Science Center), John Sahl Andersen(The University of Texas at San Antonio Health Science Center), Mace L. Rothenberg(Vanderbilt University), Connie Stephens(The University of Texas at San Antonio Health Science Center), Malcolm J. Moore(University Health Network), Manuel Modiano(The University of Texas at San Antonio Health Science Center), Peter G. Tarassoff(The University of Texas at San Antonio Health Science Center)
Cited by 5,880
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k